Boundless Bio, Inc. (BOLD) vs OKYO Pharma Limited (OKYO)
A side-by-side comparison of Boundless Bio, Inc. and OKYO Pharma Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BOLD
Boundless Bio, Inc.
$2.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
OKYO
OKYO Pharma Limited
$1.46HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BOLD vs OKYO
growth of $100 · dividends reinvested · last 3yBOLD -81.8% (-43.3%/yr)OKYO -1.3% (-0.4%/yr)OKYO compounded faster over this window
Log scale — wide-divergence pair
BOLD OKYO
BOLD vs OKYO: by the numbers
- •BOLD is the larger company ($58M vs $56M market cap).
Metrics side by side
Valuation
| Metric | BOLD | OKYO |
|---|---|---|
| P/B ratio | 0.88 | 4.54 |
Profitability
| Metric | BOLD | OKYO |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -58.99% | -72.55% |
| ROIC | -43.97% | -68.91% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.